^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Prostate Cancer
    Drug:AC0176 (Androgen receptor degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Businesswire
    Title:

    Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

    Published date:
    06/01/2022
    Excerpt:
    Accutar Biotechnology, Inc...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AC0176 for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) with disease progression on or after treatment with androgen receptor signaling inhibitors.